Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 204

Sort by

Sort Order Select

Journal Articles

Outcomes Among Adult Recipients of CAR T-cell Therapy for Burkitt Lymphoma

Blood blood.2024026831.

https://doi.org/10.1182/blood.2024026831

Published: 2025

Includes: Supplemental data

Journal Articles

Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML

Blood blood.2024025154.

https://doi.org/10.1182/blood.2024025154

Published: 2025

Includes: Supplemental data

Journal Articles

Outcomes after Bone Marrow Versus Peripheral Blood Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide-Based Graft Versus Host Disease Prophylaxis

Moazzam Shahzad, Aleenah Mohsin, Muhammad Kashif Amin, Aqeeb Ur Rehman, Sibgha Gull Chaudhary, Iqra Anwar, Matthew McGuirk, Mohammad Ammad Ud Din, Leyla O. Shune, Al-Ola Abdallah, Mehdi Hamadani, Joseph P. McGuirk, Muhammad Umair Mushtaq

Blood (2024) 144 (Supplement 1): 2118.

https://doi.org/10.1182/blood-2024-199442

Published: 2024

Journal Articles

Outcomes of Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis in Elderly Patients over 70 Years of Age with Acute Leukemia and Myelodysplastic Syndromes

Muhammad Umair Mushtaq, Amir Kasaeian, Sibgha Gull Chaudhary, Muhammad Kashif Amin, Naghmeh Khavandgar, Hediyeh Alemi, Muhammad Fareed Khalid, Iqra Anwar, Matthew McGuirk, Al-Ola Abdallah, Anurag K. Singh, Mehdi Hamadani, Joseph P. McGuirk, Moazzam Shahzad

Blood (2024) 144 (Supplement 1): 3543.

https://doi.org/10.1182/blood-2024-201164

Published: 2024

Journal Articles

Factors Associated with Acute and Chronic Graft-Versus-Host Disease after Matched Unrelated Donor Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide-Based GvHD Prophylaxis

Moazzam Shahzad, Aqeeb Ur Rehman, Muhammad Kashif Amin, Aleenah Mohsin, Sibgha Gull Chaudhary, Iqra Anwar, Jawad Noor, Rajat Bansal, Matthew McGuirk, Anurag K. Singh, Mehdi Hamadani, Joseph P. McGuirk, Muhammad Umair Mushtaq

Blood (2024) 144 (Supplement 1): 2147.

https://doi.org/10.1182/blood-2024-199533

Published: 2024

Journal Articles

Impact of Conditioning Intensity on Outcomes after Allogeneic Related Donor HCT with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis in Acute Leukemia and Myelodysplastic Syndromes

Muhammad Umair Mushtaq, Amir Kasaeian, Muhammad Kashif Amin, Aqeeb Ur Rehman, Naghmeh Khavandgar, Hediyeh Alemi, Sibgha Gull Chaudhary, Iqra Anwar, Matthew McGuirk, Haitham Abdelhakim, Anurag K. Singh, Mehdi Hamadani, Joseph P. McGuirk, Moazzam Shahzad

Blood (2024) 144 (Supplement 1): 2141.

https://doi.org/10.1182/blood-2024-199413

Published: 2024

Journal Articles

Impact of Minimal Residual Disease Status on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

Moazzam Shahzad, Sohaib Irfan, Muhammad Kashif Amin, Muhammad Jawad Javed, Matthew McGuirk, Sibgha Gull Chaudhary, Iqra Anwar, Zobia Farooq, Abdulraheem Yacoub, Anurag K. Singh, Mehdi Hamadani, Joseph P. McGuirk, Muhammad Umair Mushtaq

Blood (2024) 144 (Supplement 1): 3552.

https://doi.org/10.1182/blood-2024-193477

Published: 2024

Journal Articles

Factors Associated with Graft-Versus-Host Disease after Related Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis

Muhammad Umair Mushtaq, Amir Kasaeian, Muhammad Kashif Amin, Hediyeh Alemi, Naghmeh Khavandgar, Aqeeb Ur Rehman, Sibgha Gull Chaudhary, Matthew McGuirk, Al-Ola Abdallah, Anurag K. Singh, Sunil Abhyankar, Mehdi Hamadani, Joseph P. McGuirk, Moazzam Shahzad

Blood (2024) 144 (Supplement 1): 3517.

https://doi.org/10.1182/blood-2024-199559

Published: 2024

Journal Articles

Sociodemographic and Patient-Related Determinants of Outcomes after Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis

Sibgha Gull Chaudhary, Moazzam Shahzad, Kayla Pfannenstiell, Muhammad Kashif Amin, Amir Kasaeian, Naghmeh Khavandgar, Hediyeh Alemi, Sohaib Irfan, Matthew McGuirk, Syed Nasir Abbas Bukhari, Anurag K. Singh, Mehdi Hamadani, Muhammad Umair Mushtaq

Blood (2024) 144 (Supplement 1): 2122.

https://doi.org/10.1182/blood-2024-202260

Published: 2024

Journal Articles

Impact of CD34+ Graft Cell Dose on Outcomes after Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis

Sibgha Gull Chaudhary, Moazzam Shahzad, Amir Kasaeian, Muhammad Fareed Khalid, Muhammad Kashif Amin, Naghmeh Khavandgar, Hediyeh Alemi, Matthew McGuirk, Kayla Pfannenstiell, Syed Nasir Abbas Bukhari, Sunil Abhyankar, Mehdi Hamadani, Joseph P. McGuirk, Muhammad Umair Mushtaq

Blood (2024) 144 (Supplement 1): 3503.

https://doi.org/10.1182/blood-2024-201994

Published: 2024

Journal Articles

Outcomes after Bone Marrow Versus Peripheral Blood Matched Sibling Donor Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide-Based Gvhd Prophylaxis

Muhammad Umair Mushtaq, Amir Kasaeian, Sibgha Gull Chaudhary, Muhammad Kashif Amin, Hediyeh Alemi, Naghmeh Khavandgar, Iqra Anwar, Sohaib Irfan, Matthew McGuirk, Al-Ola Abdallah, Anurag K. Singh, Mehdi Hamadani, Joseph P. McGuirk, Moazzam Shahzad

Blood (2024) 144 (Supplement 1): 2119.

https://doi.org/10.1182/blood-2024-200031

Published: 2024

Journal Articles

Improving Outcomes in Plasmablastic Lymphoma: A Multicenter Experience from an American Cohort

Blood (2024) 144 (Supplement 1): 573.

https://doi.org/10.1182/blood-2024-198008

Published: 2024

Journal Articles

Glofitamab in Combination with Rituximab Plus Ifosfamide, Carboplatin, and Etoposide Shows Favorable Efficacy and Manageable Safety in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Eligible for Stem Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: Results from a Phase Ib Study

Catherine S. Diefenbach, Paolo F. Caimi, Nakhle S Saba, Fernando Vargas Madueno, Mehdi Hamadani, Luis E. Fayad, Peter A. Riedell, Andrew Gillis-Smith, Stephen Simko, Victor Orellana-Noia, Maria Filippou-Frye, Amy V. Kapp, James Relf, Linda Lundberg, Lauren C. Pinter-Brown

Blood (2024) 144 (Supplement 1): 987.

https://doi.org/10.1182/blood-2024-198452

Published: 2024

Journal Articles

Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Blood (2024) 144 (Supplement 1): 470.

https://doi.org/10.1182/blood-2024-199723

Published: 2024

Journal Articles

Single-Agent Ibrutinib Versus Allogeneic Hematopoietic Cell Transplantation for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and del(17p)

Farrukh T. Awan, Ran Liu, Hsin-Hui Huang, Matthew Bye, Kwang Wooahn, Gabriel S. Krigsfeld, Anat Raz, Heather R Wolfe, Mehdi Hamadani

Blood (2024) 144 (Supplement 1): 2178.

https://doi.org/10.1182/blood-2024-194156

Published: 2024

Journal Articles

Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis

Blood (2024) 144 (Supplement 1): 1042.

https://doi.org/10.1182/blood-2024-193827

Published: 2024

Journal Articles

Early Safety and Feasibility Results from a Phase II Trial of De-Escalated Ptcy and Ruxolitinib for Gvhd Prophylaxis in Older Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT

Sameem Abedin, Fateeha Furqan, Lyndsey Runaas, Walter Longo, Nirav N. Shah, Timothy S. Fenske, Marcelo C. Pasquini, William R Drobyski, Xue-Zhong Yu, Mehdi Hamadani

Blood (2024) 144 (Supplement 1): 1039.

https://doi.org/10.1182/blood-2024-200832

Published: 2024

Journal Articles

Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Blood (2024) 144 (Supplement 1): 526.

https://doi.org/10.1182/blood-2024-199139

Published: 2024

Journal Articles

Application of Stem Cell Boost for Immune Effector Cell Associated Hematotoxicity (ICAHT) Following BCMA Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Multiple Myeloma (MM)

Blood (2024) 144 (Supplement 1): 254.

https://doi.org/10.1182/blood-2024-210725

Published: 2024

Journal Articles

Socioeconomic Disparities in Allogeneic Hematopoietic Cell Transplant Outcomes

Moazzam Shahzad, Zouina Sarfraz, Ben Ponvilawan, Muhammad Kashif Amin, Ankita Gupta, Matthew McGuirk, Sibgha Gull Chaudhary, Iqra Anwar, Leyla O. Shune, Joseph P. McGuirk, Mehdi Hamadani, Muhammad Umair Mushtaq

Blood (2024) 144 (Supplement 1): 3556.

https://doi.org/10.1182/blood-2024-194451

Published: 2024

NARROW

Outcomes Among Adult Recipients of CAR T-cell Therapy for Burkitt Lymphoma

Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML

Outcomes after Bone Marrow Versus Peripheral Blood Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide-Based Graft Versus Host Disease Prophylaxis

Outcomes of Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis in Elderly Patients over 70 Years of Age with Acute Leukemia and Myelodysplastic Syndromes

Factors Associated with Acute and Chronic Graft-Versus-Host Disease after Matched Unrelated Donor Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide-Based GvHD Prophylaxis

Impact of Conditioning Intensity on Outcomes after Allogeneic Related Donor HCT with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis in Acute Leukemia and Myelodysplastic Syndromes

Impact of Minimal Residual Disease Status on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

Factors Associated with Graft-Versus-Host Disease after Related Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis

Sociodemographic and Patient-Related Determinants of Outcomes after Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based GvHD Prophylaxis

Impact of CD34+ Graft Cell Dose on Outcomes after Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis

Outcomes after Bone Marrow Versus Peripheral Blood Matched Sibling Donor Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide-Based Gvhd Prophylaxis

Improving Outcomes in Plasmablastic Lymphoma: A Multicenter Experience from an American Cohort

Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): First Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Single-Agent Ibrutinib Versus Allogeneic Hematopoietic Cell Transplantation for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and del(17p)

Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis

Early Safety and Feasibility Results from a Phase II Trial of De-Escalated Ptcy and Ruxolitinib for Gvhd Prophylaxis in Older Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT

Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Application of Stem Cell Boost for Immune Effector Cell Associated Hematotoxicity (ICAHT) Following BCMA Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Multiple Myeloma (MM)

Socioeconomic Disparities in Allogeneic Hematopoietic Cell Transplant Outcomes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only